Cannabioids as a New Intervention for Amphetamine Dependence

Cannabinoids as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02952196

Enrollment

Registered

2016-11-02

Start date

2016-11-30

Completion date

2017-12-31

Last updated

2020-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphetamine Addiction

Keywords

Amphetamine, Cannabinoids

Brief summary

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

Interventions

DRUGdrug administration

administering drug to patient with amphetamine addiction

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Current DSM-V criteria for amphetamine use disorder * Ability to give valid, informed consent

Exclusion criteria

* Severe and/or unstable hepatic, neurologic (including diagnosis of seizures), cardiac (including arrhythmias) or renal disease, or any other severe or unstable medical condition that precludes safe participation in the study according to the study physician. * Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or severe suicidality * Any serious medical condition or psychiatric illness that precludes the subject from signing the informed consent form

Design outcomes

Primary

Measure	Time frame	Description
assessing amphetamine craving	everyday during the study (that will last 3 days for each participants)	using questionnaire to assess craving and taking vital signs

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026